✨ Onyx Summary Avidity Biosciences (Nasdaq: RNA) entered into a definitive agreement to be acquired by Novartis AG for $72.00 per share in cash, valuing Avidity at approximately $12 billion, following the planned spin-off of its early-stage precision cardiology programs into a new public company, SpinCo. The transaction, unanimously approved
✨ Onyx Summary Guardant Health (Nasdaq: GH) announced new data to be presented at the 2025 American College of Gastroenterology Annual Meeting demonstrating that its FDA-approved Shield blood test achieved over 90% adherence for colorectal cancer screening, significantly higher than traditional methods. The company also shared survey findings showing patient preference
✨ Onyx Summary Kyverna Therapeutics (Nasdaq: KYTX) reported positive Phase 1 results from an investigator-initiated trial of KYV-101, its CD19 CAR T-cell therapy, in treatment-refractory rheumatoid arthritis, showing strong CAR T-cell expansion, full B-cell depletion, and meaningful clinical responses with no high-grade adverse events. Presented by Charité – University of Berlin at
✨ Onyx Summary Phathom Pharmaceuticals (Nasdaq: PHAT) announced the publication of additional analyses from its Phase 3 pHalcon-NERD-301 trial in The American Journal of Gastroenterology, demonstrating that VOQUEZNA® (vonoprazan) significantly improved nighttime reflux symptoms in patients with Non-Erosive Reflux Disease (NERD). The results highlight VOQUEZNA’s sustained nocturnal symptom relief and
✨ Onyx Summary Eli Lilly and Company (NYSE: LLY) announced a definitive agreement to acquire Adverum Biotechnologies (Nasdaq: ADVM) and its lead gene therapy candidate, Ixo-vec, for up to $12.47 per share, including $3.56 in cash and a contingent value right worth up to $8.91 based on future
✨ Onyx Summary Perspective Therapeutics (NYSE American: CATX) announced it will report third-quarter 2025 financial results and provide a business update on November 10, 2025, after market close. The company continues advancing its 212Pb-based theranostic platform with active Phase 1/2a trials in neuroendocrine tumors, melanoma, and solid tumors, supported by
✨ Onyx Summary Ocugen (Nasdaq: OCGN) announced it will host a conference call and webcast on November 5, 2025, at 8:30 a.m. ET to discuss third-quarter financial results and provide a business update, with a pre-market earnings release scheduled for the same day. MALVERN, Pa., Oct. 23, 2025 (GLOBE
✨ Onyx Summary Phathom Pharmaceuticals (Nasdaq: PHAT) announced its participation at the 2025 American College of Gastroenterology Annual Scientific Meeting, where it will highlight VOQUEZNA® (vonoprazan) as an approved treatment for gastroesophageal reflux disease (GERD) through a product theater presentation and exhibit booth engagement. The company aims to strengthen its leadership
✨ Onyx Summary Nuvation Bio (NYSE: NUVB) announced the enrollment of the first patient in Part 2 of its global G203 trial evaluating safusidenib, an oral IDH1 inhibitor, as maintenance therapy for high-grade IDH1-mutant astrocytoma following standard treatment. The study, now expanding into a Phase 3 registration trial with approximately 300
✨ Onyx Summary Kyverna Therapeutics (Nasdaq: KYTX) announced it will host a conference call on October 29, 2025, to discuss interim Phase 2 data from the KYSA-6 trial evaluating KYV-101, its CD19 CAR T-cell therapy, in generalized myasthenia gravis. The data will be presented at the AANEM Annual Meeting, highlighting progress
✨ Onyx Summary Geron Corporation (Nasdaq: GERN) granted inducement equity awards totaling approximately 3.08 million shares to four newly hired employees, including stock options and restricted stock units, under its 2018 Inducement Award Plan. The awards, approved by the Board’s Compensation Committee pursuant to Nasdaq Rule 5635(c)(4)
✨ Onyx Summary Keros Therapeutics (Nasdaq: KROS) launched a cash tender offer to repurchase up to $194.4 million of its common stock at $17.75 per share as part of its previously announced $375 million capital return program. The buyback, funded from existing cash reserves, underscores the company’s strategy
✨ Onyx Summary Perspective Therapeutics (NYSE American: CATX) reported updated interim results from its ongoing Phase 1/2a trial of [212Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2-expressing neuroendocrine tumors, showing strong tolerability with no dose-limiting toxicities and encouraging anti-tumor activity, including confirmed responses in 44% of patients with uniform
✨ Onyx Summary Verily announced the launch of Verily Me, a new consumer health app showcased at HLTH USA 2025, designed to integrate clinical insights, personal health data, and AI assistance to help users manage their health and close care gaps. Built on Verily’s precision health platform and linked to
✨ Onyx Summary Foghorn Therapeutics (Nasdaq: FHTX) announced new development progress for its Selective ARID1B degrader program, which will be featured in a keynote presentation at the 8th Annual TPD and Induced Proximity Summit on October 29, 2025. The company will follow with a virtual investor event on October 30 to
✨ Onyx Summary Seer, Inc. (Nasdaq: SEER) announced it will report third quarter 2025 financial results on November 6, 2025, followed by a webcasted conference call. The update comes as Seer continues to expand adoption of its Proteograph Product Suite, reinforcing its position as a leading provider of scalable, high-precision proteomic
![Perspective Therapeutics Presents Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the ESMO Congress 2025](/content/images/size/w1304/format/webp/2025/11/Perspective.png)
